Design,Synthesis and Biological Activities of N-(Furan-2-ylmethyl)-1H-indole-3-carboxamide Derivatives as Epidemal Growth Factor Receptor Inhibitors and Anticancer Agents
查看参考文献31篇
|
文摘
|
A series of N-(furan-2-ylmethyl)-1H-indole-3-carboxamide derivatives(6a-6p) was designed and synthesized for developing novel indole scaffolds as anticancer agents targeting the epidemal growth factor receptor (EGFR), and the cytotoxic activities of the target compounds were evaluated against three EGFR high-expressed cancer cell linesfhuman lung adenocarcinoma cell line(A549), Henrietta Lacks strain of cancer cell line(HeLa) and human colorectal cancer cell line(SW480)], one EGFR low-expressed cell line(human liver cancer cell line, HepG2) and one human liver normal cell line(HL7702) using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Some target compounds exhibited potent anticancer activities against A549, HeLa, SW480 and weak activities on HepG2, which signifies that the target compounds are likely to be EGFR inhibitors as expected. And they showed weak cytotoxic effects on HL7702, which implies the target compounds are probably to be of low toxicity against normal cells. Among them, the target compound 1-ethyl-N-(furan-2-ylmethyl)-5-{2-{[2-(2-methoxy-phenoxy)ethyl]amino}-2-oxoethoxy} -2-methyl-1H-indole-3-carboxamide(6p) with 2-{[2-(2-methoxyphenoxy)ethyl]-amino}-2-oxoethoxy group at the C5 position of the N-(furan-2-ylmethyl)-lH-indole-3-carboxamide scaffold exhibited the most potent anticancer activity. Also the binding interaction of the target compound 6p with EGFR was explored by molecular docking. Conclusively, the novel indole scaffold may be beneficial to investigate new anticanc er agents for targeting the EGFR. |
|
来源
|
Chemical Research in Chinese Universities
,2017,33(3):365-372 【核心库】
|
|
DOI
|
10.1007/s40242-017-7041-x
|
|
关键词
|
Anticancer activity
;
Epidemal growth factor receptor(EGFR) inhibitor
;
N-(Furan-2-ylmethyl)- 1H-indole-3-carboxamide derivative
|
|
地址
|
1.
Shenyang Pharmaceutical University, Key Laboratory of Structure-based Drug Design & Discovery, Ministry of Education, Shenyang, 110016
2.
Department of Pharmacy, General Hospital of Shenyang Military Area Command, Shenyang, 110016
|
|
语种
|
英文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
1005-9040 |
|
学科
|
化学 |
|
基金
|
国家自然科学基金
;
the Program for the Innovative Research Team of the Ministry of Education of China
|
|
文献收藏号
|
CSCD:6018836
|
参考文献 共
31
共2页
|
|
1.
Pines G.
FEBS. Lett,2010,584(12):2699
|
被引
4
次
|
|
|
|
|
2.
Vogelstein B.
Nat. Med,2004,10(8):789
|
被引
68
次
|
|
|
|
|
3.
Misale S.
Nat. Commun,2015,6:8305
|
被引
2
次
|
|
|
|
|
4.
Domvri K.
J. Cancer,2013,4(9):736
|
被引
1
次
|
|
|
|
|
5.
Koh P K.
Cancer Treat Rev,2012,38(6):626
|
被引
2
次
|
|
|
|
|
6.
Nyati M K.
Nat. Rev. Cancer,2006,6(11):876
|
被引
6
次
|
|
|
|
|
7.
Yarden Y.
Nat. Rev. Mol. Cell Biol,2001,2(2):127
|
被引
136
次
|
|
|
|
|
8.
Brand T M.
Radiother. Oncol,2013,108(3):370
|
被引
8
次
|
|
|
|
|
9.
Fujii M.
Int. J. Clin. Oncol,2014,19(2):220
|
被引
2
次
|
|
|
|
|
10.
Starok M.
Biomacromolecules,2015,16(5):1634
|
被引
3
次
|
|
|
|
|
11.
Robert R J.
Pharmacol. Res,2014,87(1):42
|
被引
1
次
|
|
|
|
|
12.
Boraei A T A.
Eur. J. Med. Chem,2017,125(1):360
|
被引
4
次
|
|
|
|
|
13.
Gul W.
Life Sci,2005,78(5):442
|
被引
12
次
|
|
|
|
|
14.
Ishikura M.
Nat. Prod. Rep,2010,27(11):1630
|
被引
4
次
|
|
|
|
|
15.
Kochanowska-Karamyan A J.
Chem. Rev,2010,110(8):4489
|
被引
41
次
|
|
|
|
|
16.
Sweidan K.
Bioorg. Med. Chem. Lett,2016,26(11):2685
|
被引
2
次
|
|
|
|
|
17.
Finlay M R V.
J. Med. Chem,2014,57(20):8249
|
被引
32
次
|
|
|
|
|
18.
Showalter H.
J. Med. Chem,1999,42(26):5464
|
被引
2
次
|
|
|
|
|
19.
Hempel C.
Med. Chem. Commun,2016,7(11):2159
|
被引
1
次
|
|
|
|
|
20.
Aziz Y M A.
Chem. Pharm. Bull,2015,63:1015
|
被引
1
次
|
|
|
|
|
了解气象卫星更多信息，请访问